Hepatic angiosarcoma: Pitfalls in establishing a diagnosis

Katerina Flabouris1,2, Suzanne McKeen2, Deborah Chaves Gomes3, Debajyoti Chaudhuri1 and Patrick Russell2

Abstract
Hepatic angiosarcomas are rare, deceptive and aggressive malignancies that remain notoriously difficult to diagnose and treat. This case report discusses some of the common challenges faced by clinicians, and potential clinical, radiological and histological clues to this often elusive diagnosis.

Keywords
Hepatic angiosarcoma, liver, malignancy, bleeding

Date received: 24 February 2021; accepted: 30 August 2021

Introduction
Hepatic angiosarcomas are rare, high-grade and malignant vascular neoplasms that are particularly prone to bleeding. They account for roughly 2% of all primary liver cancers1 and are typically seen during the sixth and seventh decades of life, with a male predilection of 3:1.2

Exposures to several agents have previously been implicated in the pathogenesis of hepatic angiosarcomas, including vinyl chloride,3 arsenic,4 anabolic steroids2 and thorium dioxide,5 but at least 60% of cases now have no known underlying causative factors.6

Case
A 53-year-old woman was referred to the emergency department of a tertiary centre with a 4-week history of right upper quadrant abdominal pain. She had no relevant medical history or exposure history. She never smoked, rarely consumed alcohol and took no regular medications. Apart from tender hepatomegaly, physical examination was largely unremarkable. Her laboratory tests revealed normal haemoglobin and liver enzyme levels, but mild thrombocytopenia (platelet count = 138 × 109/L, n = 150–450) and an elevated lactate dehydrogenase (LDH = 518U/L, n = 120–250). Her d-dimer was grossly elevated at 28.25 mg/L (n = 0.0–0.5 mg/L) with otherwise normal coagulation studies.

Multiphase computed tomography (CT) demonstrated multiple liver lesions with high attenuation on the non-contrast study compatible with intra-lesional haemorrhage (Figure 1(a)). There were also scattered foci of nodular enhancement on the arterial phase and low attenuation on the portal venous phase (Figure 1(b)). There was no other significant abnormality. Three passes were made into the right lobe to obtain CT-guided core biopsies, but a pathological diagnosis was not able to be provided from these samples. Subsequent magnetic resonance imaging (MRI) showed no features of cirrhosis; the lesions were of low T1 and high T2 signal and did not show restricted diffusion (Figure 1(c) and (d)), aside from an isolated area in the right lobe which was felt to be related to haemorrhage (Figure 1(e)). Core biopsies were repeated under ultrasound guidance, but again did not yield any malignant cells. The case was presented at the relevant multi-disciplinary meeting and a possible diagnosis of peliosis hepatitis was put forward, with differentials including hepatic epithelioid haemangioendothelioma. The patient was discharged for outpatient follow-up.

A few weeks later, the patient developed abdominal pain, hypotension and significant anaemia (haemoglobin = 74 g/L, n = 115–155). CT demonstrated acute intra-peritoneal haemorrhage but no active bleeding. It was clear that the liver lesions had significantly increased in size over the short time

1Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia
2Royal Adelaide Hospital, Adelaide, SA, Australia
3SA Pathology, Adelaide, SA, Australia

Corresponding Author:
Katerina Flabouris, Royal Adelaide Hospital, 1 Port Road, Adelaide, SA 5000, Australia.
Email: katerina.flabouris@adelaide.edu.au
interval (Figure 2(a)). A whole-body positron emission tomography (PET)/CT scan confirmed widespread malignant involvement of the liver and bones (Figure 2(b)–(d)), and a bone biopsy revealed a poorly differentiated large cell cancer of unclear source. The patient’s condition continued to deteriorate from worsening liver failure, and she died 3 months after her first presentation.

At autopsy, there was marked hepatomegaly with extensive replacement of the liver parenchyma by tumour nodules at various stages of haemorrhage, thrombosis and necrosis (Figure 3(a)). Metastatic deposits were present in the spleen, lungs and vertebrae. Histological examination revealed a tumour composed of hyperchromatic and highly pleomorphic spindled and epithelioid cells. Brisk mitotic activity was evident, with numerous atypical mitoses. Immunohistochemistry demonstrated endothelial differentiation of the tumour cells, with strong and diffuse positivity for CD31, CD34 (Figure 3(b)) and ERG. A diagnosis of hepatic angiosarcoma with multiple distant metastases was made.

**Discussion**

Hepatic angiosarcomas can be very difficult to diagnose antemortem. Clinical presentation and investigations can vary and be relatively non-specific.6-10 The radiological features can also vary widely, therefore resulting in hepatic angiosarcomas commonly being mistaken for haemangiomamas or other liver tumours.9,11 They may present as multiple hypoattenuating nodules, or single dominant masses with necrosis and irregular hypervascularity, with an average size of 7–9 cm at diagnosis.6,11,12 Furthermore, attempts at radiology-guided percutaneous biopsies may be met with limited diagnostic success due to the high rates of necrosis and haemorrhage with these tumours.8,13 Alternative approaches such as open biopsy may need to be considered in this instance.

While there are some potential clues to the diagnosis, none are sufficient in isolation. A grossly elevated D-dimer may reflect high rates of intra-lesional thrombosis and haemorrhage.12 Serial radiological imaging may reveal the particularly aggressive growth rate of the tumour, and MRI characteristics may prove more useful than those seen on CT or ultrasound. PET imaging has also proven to be enlightening.14-16 Histologically, these tumours may be composed of pleomorphic spindle or epithelioid cells, often with bizarre or multinucleated forms and mitosis.7 Immunohistostaining is usually positive for vascular markers, including ERG transcription factor, CD31, CD34 and Factor VIII antigen.6

Hepatic angiosarcomas are as difficult to treat as they are to diagnose. They are frequently metastatic at the time of diagnosis due to their inherently aggressive nature and can rapidly progress to involve lymph nodes, lung, bone and spleen.8,17 Early surgical intervention remains a cornerstone
Figure 2. (a) CT abdomen revealing rapid interval growth with haemoperitoneum. (b) PET scan demonstrating a grossly enlarged liver containing innumerable peripheral foci of radiotracer activity with a large photopaenic area in the right lobe, and further separate foci of tracer scattered in the left lobe. There are also innumerable FDG-avid bony deposits. (c) CT pelvis revealing a pathological fracture (arrow). (d) Corresponding PET image demonstrating FDG-avid lesion in the same area.

Figure 3. (a) Macroscopic view of the liver at autopsy revealing extensive tumour infiltration. (b) Microscopic view of section of liver at autopsy revealing strongly positive staining to CD34.
of treatment. Unlike patients with certain hepatocellular carcinomas, hepatic angiosarcomas remain an absolute contraindication for liver transplantation. There is, however, a potential role for trans-arterial chemoembolisation (TACE), particularly in cases complicated by acute bleeding. Anthracycline-based chemotherapy regimens tend to predominate, and research is ongoing into alternative agents. Nevertheless, overall median survival remains poor, even compared to other soft tissue sarcomas, with some estimates of as little as 6 months, even with treatment. Death is usually due to liver failure or intra-abdominal bleeding.

**Conclusion**

Hepatic angiosarcomas are rare, aggressive and deceptive malignancies, frequently complicated by intra-abdominal bleeding. Radiological findings can be misleading but rapidly progressive, and histological findings on percutaneous biopsy can be ambiguous. This case emphasises the importance of careful and thorough diagnostic radiological evaluation prior to proceeding to biopsy, where more invasive approaches should be considered if percutaneous attempts are not enlightening. Early surgical resection is crucial, but often largely ineffective due to the high rates of metastasis at the time of diagnosis. Further research is required to guide future therapies.

**Acknowledgements**

We sincerely thank the patient’s family for allowing us to share her story with an aim to contribute meaningfully to the medical literature.

**Declaration of conflicting interests**

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Ethical approval**

Our institution does not require ethical approval for reporting individual cases or case series.

**Informed consent**

Written informed consent was obtained from a legally authorised representative for anonymised patient information to be published in this article.

**ORCID iD**

Katerina Flabouris https://orcid.org/0000-0001-8923-824X

**Supplemental material**

Supplemental material for this article is available online.

**References**

1. Mani H and Van Thiel DH. Mesenchymal tumors of the liver. *Clin Liver Dis* 2001; 5(1): 219–257.
2. Falk H, Herbert J, Crowley S, et al. Epidemiology of hepatic angiosarcoma in the United States: 1964-1974. *Environ Health Perspect* 1981; 41: 107–113.
3. Lee FI, Smith PM, Bennett B, et al. Occupation-related angiosarcoma of the liver in the United Kingdom 1972-1994. *Gut* 1996; 39(2): 312–318.
4. Lander JJ, Stanley RJ, Sumner HW, et al. Angiosarcoma of the liver associated with Fowler’s solution (potassium arsenite). *Gastroenterology* 1975; 68(6): 1582–1586.
5. Ito Y, Kojiro M, Nakashima T, et al. Pathomorphologic characteristics of 102 cases of thorotrast-related hepatocellular carcinoma, cholangiocarcinoma, and hepatic angiosarcoma. *Cancer* 1988; 62(6): 1153–1162.
6. Locker GY, Doroshow JH, Zwelling LA, et al. The clinical features of hepatic angiosarcoma: a report of four cases and a review of the English literature. *Medicine (Baltimore)* 1979; 58(1): 48–64.
7. Yasir S and Torbenson MS. Angiosarcoma of the liver: clinicopathologic features and morphologic patterns. *Am J Surg Pathol* 2019; 43(5): 581–590.
8. Wilson GC, Lluis N, Nalesnik MA, et al. Hepatic angiosarcoma: a multi-institutional, international experience with 44 cases. *Ann Surg Oncol* 2019; 26(2): 576–582.
9. Kim HR, Rha SY, Cheon SH, et al. Clinical features and treatment outcomes of advanced stage primary hepatic angiosarcoma. *Ann Oncol* 2009; 20(4): 780–787.
10. Maluf D, Cotterell A, Clark B, et al. Hepatic angiosarcoma and liver transplantation: case report and literature review. *Transplant Proc* 2005; 37(5): 2195–2199.
11. Koyama T, Fletcher JG, Johnson CD, et al. Primary hepatic angiosarcoma: findings at CT and MR imaging. *Radiology* 2002; 222(3): 667–673.
12. Leowardi C, Hormann Y, Hinz U, et al. Ruptured angiosarcoma of the liver treated by emergency catheter-directed embolization. *World J Gastroenterol* 2006; 12(5): 804–808.
13. Pickhardt PJ, Kitchin D, Lubner MG, et al. Primary hepatic angiosarcoma: multi-institutional comprehensive cancer centre review of multiphasic CT and MR imaging in 35 patients. *Eur Radiol* 2015; 25(2): 315–322.
14. Kamatani T, Iguchi H, Okada T, et al. Co-registered positron emission tomography/computed tomography and gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid magnetic resonance imaging features of multiple angiosarcoma of the liver. *Hepatol Res* 2014; 44(10): E297–E303.
15. Oe A, Habu D, Kawabe J, et al. A case of diffuse hepatic angiosarcoma diagnosed by FDG-PET. *Ann Nucl Med* 2005; 19(6): 519–521.
16. Zheng K, Liu Y, Cui R, et al. Primary spleen angiosarcoma with concomitant hepatic hemangiomas on 18F-FDG PET/CT. *Clin Nucl Med* 2018; 43(3): 222–223.
17. Fayette J, Martin E, Piperno-Neumann S, et al. Angiosarcomas, a heterogeneous group of sarcomas with specific behavior depending on primary site: a retrospective study of 161 cases. *Ann Oncol* 2007; 18(12): 2030–2036.
18. Orlando G, Adam R, Mirza D, et al. Hepatic hemangiosarcoma: an absolute contraindication to liver transplantation—the European Liver Transplant Registry experience. *Transplantation* 2013; 95(6): 872–877.

19. Park YS, Kim JH, Kim KW, et al. Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization. *Clin Radiol* 2009; 64(8): 779–785.

20. Young RJ, Natukunda A, Litiere S, et al. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials. *Eur J Cancer* 2014; 50(18): 3178–3186.

21. Zheng YW, Zhang XW, Zhang JL, et al. Primary hepatic angiosarcoma and potential treatment options. *J Gastroenterol Hepatol* 2014; 29(5): 906–911.